Introduction to InnModels Biotechnology 3D Organoid Platform:
The InnModels Biotechnology 3D Organoid Platform is an innovative biological research tool founded on the InnModels Biotechnology clinical oncology biological sample bank. This platform shares a consistent model system with PDC and PDX platforms, offering a seamless transition in the drug development process, from in vitro high-throughput screening to in vivo studies, ensuring the continuity and reliability of experimental data.
Here are the key features of this platform:
1. Rapid Prediction: Enables swift forecasting of the clinical efficacy rate of drugs, providing early feedback for researchers.
2. Drug Screening: Filters out trial drugs with higher developmental potential from a list of alternative compounds, optimizing resource allocation.
3. Model Selection: Based on the drug's response to the model, the most suitable model is selected for subsequent in vivo experiments.
4. Efficacy Comparison: Compares the effects with benchmark drugs or clinical therapeutic drugs to visually assess the differences in efficacy and effective model variations.
5. Disease-specific Analysis: Compares the efficacy differences across different cancer model queues to determine the optimal indications of the drug.
6. Efficacy and Resistance Analysis: Based on drug efficacy data, models are classified as either effective or drug-resistant. Furthermore, by exploring genetic feature differences between models and before and after treatments, the drug mechanism of action is deeply probed.
7. Biomarker Discovery: Models are classified based on drug efficacy, and genomic analyses of different groups' genetic feature differences aim to discover biomarkers that can predict drug efficacy.
This is a comprehensive, efficient platform that thoroughly considers experimental continuity, offering robust technical support for contemporary drug development.